Aurinia Pharmaceuticals (AUPH) Free Cash Flow (2020 - 2026)

Aurinia Pharmaceuticals' Free Cash Flow history runs 7 years deep, the most recent figure standing at $32.5 million for Q1 2026.

• Quarterly Free Cash Flow rose 2434.76% year-over-year to $32.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $167.6 million (up 160.64% YoY) and the FY2025 annual result came in at $136.4 million, up 207.05% from the prior year.
• Free Cash Flow was $32.5 million for Q1 2026 at Aurinia Pharmaceuticals, down from $45.7 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $45.7 million in Q4 2025 and bottomed at -$46.8 million in Q1 2022.
• A 5-year average of $5.9 million and a median of $10.2 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow grew 12.17% — and 2026, when it surged 2434.76%.
• Aurinia Pharmaceuticals' Free Cash Flow stood at $10.2 million in 2022, then soared by 43.63% to $14.7 million in 2023, then soared by 104.94% to $30.2 million in 2024, then surged by 51.43% to $45.7 million in 2025, then declined by 28.79% to $32.5 million in 2026.
• Business Quant data shows AUPH's Free Cash Flow at $32.5 million in Q1 2026, $45.7 million in Q4 2025, and $44.4 million in Q3 2025.